Drug Type Small molecule drug |
Synonyms Dimebolin, Dimebon, Latrepirdine + [4] |
Target |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date RU (01 Jan 1983), |
RegulationOrphan Drug (US) |
Molecular FormulaC21H27Cl2N3 |
InChIKeyGTWLIQOLGOZTLF-UHFFFAOYSA-N |
CAS Registry97657-92-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Dimebolin hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypersensitivity | RU | - | 01 Jan 1983 |
Rhinitis, Allergic | RU | - | 01 Jan 1983 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Huntington Disease | Phase 3 | US | 01 Jul 2009 | |
Huntington Disease | Phase 3 | US | 01 Jul 2009 | |
Huntington Disease | Phase 3 | AU | 01 Jul 2009 | |
Huntington Disease | Phase 3 | AU | 01 Jul 2009 | |
Huntington Disease | Phase 3 | CA | 01 Jul 2009 | |
Huntington Disease | Phase 3 | CA | 01 Jul 2009 | |
Huntington Disease | Phase 3 | DK | 01 Jul 2009 | |
Huntington Disease | Phase 3 | DK | 01 Jul 2009 | |
Huntington Disease | Phase 3 | DE | 01 Jul 2009 | |
Huntington Disease | Phase 3 | DE | 01 Jul 2009 |
Phase 1 | 36 | placebo (Placebo) | kqrmrfssnq(rqbymsyamv) = mcxgcujfub mmynksuium (latdpunwhp, pdimfmhjch - xoofimrcrj) View more | - | 02 Apr 2013 | ||
(Alprazolam 1 mg) | kqrmrfssnq(rqbymsyamv) = pwxvginsjk mmynksuium (latdpunwhp, ddpwkbpfty - ttpeieommj) View more | ||||||
Phase 3 | 742 | dimebon (latrepirdine) (Dimebon (Cohort 1)) | ogjuadjbti(ksjzgsgsoa) = ceutgunarg xcpmmfbmmb (tijeukmivr, ezofonoeik - iisthyfcji) View more | - | 08 Feb 2013 | ||
Placebo (Placebo (Cohort 1)) | ogjuadjbti(ksjzgsgsoa) = vxvhfikobu xcpmmfbmmb (tijeukmivr, kpfyxrchlz - kjusltibbg) View more | ||||||
Phase 3 | 403 | gkielaeayr(utgpkprjke) = bqosggpfbu wtwoxzczae (aiuldxewil ) | Negative | 01 Jan 2013 | |||
Placebo | gkielaeayr(utgpkprjke) = dtinmjvyda wtwoxzczae (aiuldxewil ) | ||||||
Phase 3 | 649 | Dimebon (latrepirdine) | tobrkjngtu(pvxsxzkwmo) = ammvwhwcal qawwcfrdvw (gjuosyklfq, judinnchik - miszoqzgcb) View more | - | 14 Nov 2012 | ||
Phase 3 | 5 | wrpuwptfkp(vlmpmpwirx) = xmqmrvdzxt fkrbizxjro (zbbkqqyxqy, gpsfazsofw - nvnqrtilet) View more | - | 02 Oct 2012 | |||
Phase 3 | 86 | (Dimebon) | fvazvnkdug(vyhirbrfqt) = kypkyyxrxw ofgmyaedjo (tarklhkjjf, brzhfgicfe - tyavbwhges) View more | - | 02 Oct 2012 | ||
Placebo po TID (Placebo) | fvazvnkdug(vyhirbrfqt) = aqeivsokjv ofgmyaedjo (tarklhkjjf, fojptqjtkm - vxejchplgc) View more | ||||||
Phase 2 | 91 | jrzyveerpo(lopkvfpkdn): treatment effect = 0.97 (95% CI, 0.1 - 1.85) | - | 01 Feb 2010 | |||
Placebo | |||||||
Not Applicable | 183 | cynylxncrb(wtbytghand) = Dimebon was well-tolerated in both mild and moderate AD patients through one year, with dry mouth as the most common drug-related adverse event (%) reported qufijkthaw (neoyzkljef ) | Positive | 01 Jul 2008 | |||
Not Applicable | 183 | zwlxujifww(pwhxeqnipr) = rkrhbgojdu ckgsedmgob (yqykaljocs ) View more | - | 01 Jul 2007 |